ANTICANCER RESEARCH
International Journal of Cancer Research and Treatment
ISSN: 0250-7005

PKC Potentiates Tyrosine Kinase Inhibitors STI571 and Dasatinib Cytotoxic Effect

ARACELI TOBÍO, AMPARO ALFONSO and LUIS M. BOTANA

Pharmacology Department, School of Veterinary Sciences, University of Santiago de Compostela, University Campus, Lugo, Spain

Reprinted from
ANTICANCER RESEARCH *34*: 3347-3356 (2014)

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

HighWire Press® STANFORD UNIVERSITY

ISSN (print): 0250-7005
ISSN (online): 1791-7530

Editorial Board

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

E-mails: Editorial Office: journals@iiar-anticancer.org
Managing Editor: editor@iiar-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research.

For more information about ANTICANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: www.iiar-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

Annual Subscription Rates 2014 per volume: Institutional subscription Euro 1,650.00 - print or online. Personal subscription Euro 780.00 - print or online. Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-33, 1981-2013) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. Cheques should be made payable to J.G. Delinasios, Executive Publisher of Anticancer Research, Athens, Greece, and should be sent to the Editorial Office.

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científíca (SIIC) Data Bases.

D.T.P. BY IIAR
PRINTED BY ENTYPO, ATHENS, GREECE
PRINTED ON ACID-FREE PAPER

PKC Potentiates Tyrosine Kinase Inhibitors STI571 and Dasatinib Cytotoxic Effect

ARACELI TOBÍO, AMPARO ALFONSO and LUIS M. BOTANA

Pharmacology Department, School of Veterinary Sciences, University of Santiago de Compostela, University Campus, Lugo, Spain

Abstract. *Aim: The aim of the present study was to determine the relationship between the tyrosine kinase inhibitors, STI571 and dasatinib effects and protein kinase C (PKC) status in HMC-1^{560} and HMC-1^{560,816} cell lines. Material and Methods: Viability results were obtained by two different methods: MTT and a flow cytometry with Annexin V-FITC/PI double-staining protocol. The lipid-based transfection method was used to silence PKC. Results: Long-term PKC activation induces apoptosis in both HMC-1 cell lines. Moreover, PKC activation potentiates STI571 and dasatinib cytotoxic effects in HMC-1^{560} and HMC-1^{560,816} cells, respectively, by increasing necrotic populations. To investigate this PKC effect, the role of PKCδ, an isoform intimately related with apoptotic cell death, was studied. The results obtained evidence that either STI571 or dasatinib apoptotic cell death are PKCδ-dependent. Particularly, STI571 showed less dependence to PKCδ than dasatinib. Conclusion: PKCδ modulation is essential and determines mastocytosis treatment effectiveness, since STI571 and dasatinib effects are PKCδ-dependent.*

Allergic responses are characterized by a cascade of events that lead to an immediate hypersensitivity reaction in which mast cells (MCs) have a crucial role. MCs are derived from CD34$^+$, CD117$^+$ (c-kit$^+$) and CD13$^+$ bone marrow progenitors and release several inflammatory mediators to the bloodstream after their activation (1). MCs produce several mediators and express the high-affinity IgE receptor (FCεRI). Two different subtypes, MC_T and MC_{TC}, were described after immunohistochemical studies in human tissues, depending on the presence of tryptase (MC_T) or tryptase+chymase (MC_{TC}) simultaneously. However, this classification is controversial since recent studies have demonstrated that all MCs are able to produce chymase. Out of all the inflammatory mediators produced by MCs, histamine, prostaglandin D2 and platelet-activating factor (PAF) contribute to induce symptoms after MC activation (MCA). MCA syndrome (MCAS) is a term applied when one or various of these three criteria are present: 1) chronic or recurrent clinical signs, 2) MCs are present and 3) the symptoms respond to MC-stabilizing agents therapy or drugs against MC mediators are used (2). In this context, MCAS are sub-divided into three variants: 1) primary MCAS, with c-kit D816V$^+$-mutated clonal MCs, 2) secondary MCAS, in patients with allergy or atopic disorder without clonal MCs, 3) idiopathic MCAS, patients that fulfill the three criteria but do not have allergen-specific IgE and clonal MCs (3). Along with MCAS, two other MC disorders have been described, MC hyperplasia and mastocytosis. Firstly, MC hyperplasia is defined as an increase of tissue MCs as a consequence of different disorders like chronic infections or cancer. Secondly, (mono)clonal MCs increase is named mastocytosis and can be sub-divided into cutaneous mastocytosis (CM), systemic mastocytosis (SM) and localized MCs tumors (4).

The c-kit ligand stem cell factor (SCF), also named MC growth factor, steel factor or kit ligand, activates MCs. Nevertheless, the human mast cell line (HMC)-1 is SCF-independent. Two different HMC-1 sublines have been described: HMC-1^{560} and HMC-1^{560,816}. HMC-1 cell lines do not have FCεRI receptors in the cellular surface, unlike human tissue MCs. Either HMC-1^{560} or HMC-1^{560,816} sublines have the Val560 >Gly mutation at codon 560 in the juxtamembrane position of c-kit. This mutation implies that c-kit receptor is constitutively phosphorylated and therefore does not need SCF for its activation (5). On the other hand, the second subline has another c-kit mutation; Asp816 >Val at codon 816. Mastocytosis is characterized by c-kit mutant MCs abnormal growth and expansion (*e.g.* Asp-816 to Tyr or Asp-816 to Phe). Specifically, Asp-816 to Val$^+$ cells are present in 80% of the patients with SM. This Asp816 >Val mutation was firstly described in adult patients with SM and was defined as rare in pediatric cases. However, the presence of Asp816 >Val$^+$

Abbreviations: PKC: Protein kinase C, HMC-1: human mast cell line, TyrK: tyrosine kinase.

Correspondence to: Luis M. Botana, Dept. Farmacología, Fac. Veterinaria, 27002 Lugo, Spain. Tel/Fax: +34 982822233, e-mail: Luis.Botana@usc.es

Key Words: HMC-1, PKC, c-kit, STI571, dasatinib, PMA.

cells in the 42% of pediatric patients was more recently described (6). C-kit mutations are not only present in matocytosis, since are also described in Ewing's tumors, thymic and ovarian cancers, neuroblastoma or adenoid cystic carcinoma. For SM treatment, several drugs have been used, such as interferon-α (IFN-α), the nucleoside analog 2-chlorodeoxyadenosine cladribine and the group of tyrosine kinase (TyrK) inhibitors. Chronic myeloid leukemia (CML) is a disorder present in patients with SM. SM with associated clonal haematological non-mast cell lineage disease (SM-AHNMD) is the name of this SM type (7). CML was the first cancer associated with an oncogene marker, the Philadelphia chromosome, characterized by a chromosome translocation which leads to Breakpoint Cluster Region-Abelson Leukaemia (Bcr-Abl) oncogene formation. TyrK inhibitors have been widely used in SM-AHNMD treatment, since most of them inhibit other Src family kinases as well as c-kit receptor (8). Imatinib (Signal Tranduction Inhibitor (STI) 571 or Gleevec®) was the first TyrK inhibitor used. This drug has activity against several oncogenic TyrKs: Bcr-Abl, c-kit, platelet-derived growth factor receptor, discoidin domain receptor and colony-stimulating factor receptor-1. Imatinib resistances emergence and its inefficiency against HMC-$1^{560,816}$ cell line gave birth to the second generation of TyrK inhibitors, including compounds such as dasatinib (BMS354825), nilotinib (AMNI07), midostaurin (PKC412) and bosutinib (SKI-606) (9). The multikinase inhibitor dasatinib is able to inhibit Bcr-Abl, c-kit, PDGRF and ephrin receptor kinase (10). Interestingly, it is a good choice to induce cell death in HMC-$1^{560,816}$ cells, unlike imatinib. Also, dasatinib+midostaurin combination shows a synergistic effect indicating that different TyrK inhibitors co-treatment is an usable tool for SM and CML treatment (11).

PKC plays a primordial role on MCs activation and degranulation, therefore, the PKC effect in mastocytosis has been described in several studies (12,13). PKC is a family of serine/threonine kinases with different isoforms divided into three classes depending on their sensitivity to Ca^{2+} and phorbol esters: (1) Ca^{2+}-dependent isozymes (or cPKCs); α, β_1, β_2 and γ that are activated by diacylglicerol (DAG) or 12-O-tetradecanoylphorbol-13-acetate (PMA); (2) Ca^{2+}-independent isozymes (or novel PKCs); δ, ε, η, μ and θ, activated by PMA; and (3) atypical isozymes (ζ and ι/λ), which are PMA and Ca^{2+}-independent. PKC activation has been described as an essential signal for MC exocytosis (14). Src TyrKs family activation is considered as a proximal event for MC activation and its relationship with PKC isoforms has been widely studied. Src belongs to a 11-member family, including Lyn. Specifically, Syk, Btk, Lyn and Fyn are proteins related with exocytosis granules (15). Hence, in order to determine receptor-proximal TyrKs role on MCs secretory granules, gene-inactivated mice were used. Out of all, Lyn is the only protein that is not essential for MC exocytosis, whereas exocytosis is abrogated in Fyn, Syk and Btk-deficient MCs. Interestingly, PKCα and PKCβ II activation is increased upon FcεRI stimulation in $lyn^{-/-}$ MCs (16). Also, cell degranulation is restored by PKCβ and Ca^{2+} in RBL-2H3 cells, together with PKCβ membrane translocation. In addition, IL-6 production and degranulation are inhibited in PKCβ-deficient MCs (17). PKCδ is another important isoform related with MC exocytosis regulation. Specifically, SHIP/Shc/PKCδ complex is essential to regulate MC exocytosis, therefore, possible molecules that interact with SHIP, like PKCδ, might modulate MC degranulation (18).

As it has been shown, either PKC or TyrK inhibitors take part on intracellular pathways in which Src proteins are involved. PKC and TyrK proteins relationship has been described in several studies since PKC and TyrK inhibition is an useful tool against aberrant MCs (19). In this sense, TyrK and PKC inhibitors combination is a highly effective therapy in mastocytosis patients. Among all TyrK inhibitors that have cytotoxic effect against HMC-1 cell line, STI571 and dasatinib are two of the most potent studied (20, 21). Moreover, long-term PKC activation (PMA treatment) induces cell death in several cell lines (22, 23). Also, PKC potentiates TyrK inhibitors dasatinib and nilotinib effect in HMC-1 cell line (19). Therefore, since PKC inhibition effect over TyrK inhibitors cytotoxicities has been already described, the purpose of this study is to clarify the consequences of PKC modulation, this time through its activation.

Materials and Methods

Chemicals. STI571 was provided by Dr. Luis Escribano Mora (Centro de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Carmen, Toledo, Spain). Dasatinib (sc-358114), negative siRNA control (sc-37007) and PKCδ siRNA (sc-36253) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PMA and bovine serum albumin (BSA) were from Sigma-Aldrich (Madrid, Spain). Phosphate buffered saline (PBS) was from Invitrogen (Barcelona, Spain). Anti Mouse IgG was purchased from GE Healthcare (Barcelona, Spain). Anti β-actin and polyvinylidene flouride (PVDF) membrane were from Millipore (Temecula, CA, USA). Anti PKCδ was from BD Biosciences (Madrid, Spain). Cell Lab ApoScreen™ Annexin V and DNA Prep™ Stain were from Beckman Coulter (Fullerton, CA, USA). Polyacrylamide gels and molecular weight marker Precision Plus Protein™ Standards Kaleidoscope™ were from BioRad (Barcelona, Spain). GeneSilencer® was from Genlantis (San Diego, CA, USA).

Cell cultures. HMC-1^{560} cells were kindly provided by Dr. J. Butterfield (Mayo Clinic, Rochester, MN) and HMC-$1^{560,816}$ cells were kindly provided by Dr. Luis Escribano Mora with permission from Dr. J. Butterfield. They were maintained at 37˚C in Iscove's modified Dulbecco's medium (IMDM) (Gibco, Invitrogen, Spain) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen, Spain) and 100 IU/ml penicillin + 100 μg/ml streptomycin (Gibco, Invitrogen, Spain) in an atmosphere containing 5% CO_2. The medium was re-newed once a week.



Figure 1. *Effect of tyrosine kinase inhibitors, STI571 and dasatinib, and PKC activation on cell viability of the HMC-1 cell line. (A) HMC-1^{560} cells and (B) HMC-1^{560,816} cells. Cells were incubated for 48 h with 25 nM STI571, 0.012 μM (HMC-1^{560}) and 0.6 μM (HMC-1^{560,816}) dasatinib and 100 ng/ml PMA at 37˚C. Mean±SEM of three experiments. *Significant differences between untreated and treated cells. (A) #significant differences between STI571- and STI571+PMA-treated cells. (B) #Significant differences between dasatinib- and dasatinib+PMA-treated cells.*

MTT assay. HMC-1^{560} and HMC-1^{560,816} cell lines were incubated with STI571, dasatinib and PMA for 48 h at 37˚C. Then cells were washed with saline solution and incubated with MTT (250 μg/ml) for 30 min. After washing with saline solution cells were re-suspended in 200 μl of water and sonicated for 1 min. Absorbance was determined in a Bio-Tek Synergy 4 plate reader at wave length of 595 nm.

Apoptotic and necrotic cell death determination by flow cytometry. Apoptosis was detected by Annexin-V-FITC/PI staining using the Cell Lab ApoScreen™ Annexin V kit. HMC-1^{560} and HMC-1^{560,816} cells were incubated with STI571, dasatinib and PMA for 48 h (37˚C). Then cells were prepared exactly following the manufacturer's instructions and an Amnis Corporation IS-100 flow cytometer was used.

Transfection by lipid-based method. GeneSilencer® (Genlantis) was composed by the transfection reagent and the diluent. The manufacturer's instructions were followed carefully. On the day of transfection two solutions were prepared. Solution A, composed by diluent, FBS/antibiotic –free IMDM medium and PKCδ siRNA. Control siRNA (sc-37007) was used as negative control for evaluating RNAi off-target effects. Solution B was composed by transfection reagent diluted in FBS/antibiotic-free IMDM medium. Solutions A and B were mixed and incubated for 5 min at room temperature. HMC-1^{560} cells were incubated in a total volume of 500 μl in a FBS/antibiotic-free IMDM medium. Cellular concentration was 2×10^6/ml. 500 μl of IMDM (supplemented with 20% FBS and Penicillin/Streptomicyn 2×) were added to HMC-1^{560} cells after 5 h transfection. 19 h later cells were incubated with STI571, dasatinib and PMA. HMC-1 cells were incubated with the different compounds for 48 h at 37˚C.

Western blotting. Cells were re-suspended in 80 μl lysis buffer with the follow composition: 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1%Triton X-100, 1× complete protease inhibitor (Roche, Madrid (Madrid) Spain) and 1x phosphatase inhibitor cocktail (Roche, Madrid (Madrid) Spain). Protein concentration determination was carried out by using Bradford assay and BSA as protein standard. For separating proteins according to their molecular weight sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) procedure was used. Proteins were transferred to a PVDF membrane which was blocked with 0.5% BSA and then it was incubated for 10 min with anti PKCδ (1:1,000). After two washes with washing buffer (PBS+0.1%Tween), the membrane was incubated for 10 min with the secondary antibody anti-Mouse IgG conjugated with horseradish peroxidase. A chemiluminescence detection kit (SuperSignal West Femto; Pierce, Rockford, IL, USA) was used to determine protein expression levels. Relative protein expression was calculated in relation to β-actin (0.3:1,000).

Statistical analysis. Results were analyzed using the Student's *t*-test for unpaired data. A probability level of 0.05 or smaller was used for statistical significance. Results were expressed as the mean±SEM.

Results

PKC activation effect over STI571 and dasatinib cytoxicities in HMC-1^{560} y HMC-1^{560,816} cell lines. As was previously described 25 nM STI571 induces 50% cell death in HMC-1^{560} cell line whereas the IC_{50} for HMC-1^{560} and HMC-1^{560,816} are 0.012 μM and 0.6 μM dasatinib, respectively. Cells were also incubated with PMA and STI571 or dasatinib simultaneously in order to determine the long-time PKC activation effect over STI571 and dasatinib cytotoxicities. First, in HMC-1^{560} cells, a decrease of 50% and 40% on cell viability is induced by 25 nM STI571 and 0.012 μM dasatinib, respectively (Figure 1A). Also, PKC activation significantly decreased cell viability (36%), whereas PMA and STI571 co-incubation caused a higher decrease (73%) than that observed with STI571-alone. However, PMA does not potentiate the effect of dasatinib alone. In HMC-1^{560,816} cells, 0.6 μM dasatinib and PKC



Figure 2. *Effect of STI571, dasatinib and PMA treatments on population distribution (live, apoptotic and necrotic) in the HMC-1^{560} cell line. HMC-1^{560} cells were incubated for 48 h with of 25 nM STI571, 0.012 μM dasatinib and 100 ng/ml PMA at 37˚C. Live (botton left panel), apoptotic (botton right panel) and late apoptotic/necrotic cells (upper panel) were detected by Annexin V-FITC/PI staining. (A), (B), (C), (D), (E) and (F) represent one representative experiment of untreated, STI571, dasatinib, PMA, STI571+PMA and dasatinib+PMA treatments, respectively. (G) mean±SEM of the three experiments. *significant differences in live populations between the treatments. #significant differences in apoptotic populations between the treatments. **significant differences in necrotic populations between the treatments. Δsignificant differences in live population between STI571- and STI571+PMA-treated cells.*

activation cause a similar decrease on cell viability, 40 and 43%, respectively. Moreover, a higher decrease (54%) is observed after dasatinib+PMA simultaneous addition.

PKC activation-induced cell death in HMC-1 cell lines. Results presented in Figures 1A and 1B demonstrate that PMA has a potent cytotoxic effect against both MC lines,



Figure 3. *Effect of dasatinib and PMA treatments on population distribution (live, apoptotic and necrotic) in HMC-1^{560,816} cell line. HMC-1^{560,816} cells were incubated for 48 h in the presence 0.6 μM dasatinib and 100 ng/ml PMA at 37˚C. Live (botton left panel), apoptotic (botton right panel) and late apoptotic/necrotic cells (upper panel) were detected by Annexin V-FITC/PI staining. (A), (B), (C) and (D) represent one representative experiment of untreated, dasatinib, PMA and dasatinib+PMA treatments, respectively. (E) mean±SEM of the three experiments. *significant differences in live populations between the treatments. #significant differences in apoptotic populations between the treatments. **significant differences in necrotic populations between the treatments. Δsignificant differences in live population between dasatinib- and dasatinib+PMA-treated cells.*

however, the pathway followed by this kinase, apoptotic or necrotic, remains undefined. In this sense, Annexin V-FITC /PI technique was next employed to determine the distribution of the three cellular populations: live, apoptotic and necrotic in both HMC-1 cell lines. For HMC-1^{560} cell line, Figures 2A to 2F represent the intensity of Annexin V-FITC (X axis) and PI (Y axis) at different conditions and Figure 2G shows the results of three experiments. The percentage of live cells is 81% in untreated cells, whereas apoptotic and necrotic populations represent 5 and 14%, respectively. A significant decrease (from 81 to 54%) on live population is observed after STI571 treatment, accompanied with an increase on apoptotic population (from 5 to 36%). Nevertheless, the necrotic population is not modified. Moreover, a significant decrease on live population (81 to 43%) after dasatinib treatment is perceived. Dasatinib also increases the percentage of apoptotic cells (48%) whereas the necrotic population slightly increases from 5 to 15%. Besides, long-term PKC activation has a similar effect than the one induced by STI571 and dasatinib. PMA induces apoptotic cell death (41% of apoptotic cells) and does not modify necrotic population. Drug combinations tested, STI571+PMA and dasatinib+PMA, decrease cell viability inducing apoptosis (53% and 32% of apoptotic cells for STI571+PMA and dasatinib+PMA treatments, respectively). Moreover, STI571+PMA induces an increase on necrotic cell death (30%), not observed after dasatinib+PMA treatment. In the HMC-1^{560,816} cell line, the distribution of different populations is represented in Figures 3A (untreated), 3B (dasatinib), 3C (PMA) and 3D (dasatinib+PMA), while Figure 3E shows the mean of three experiments. As Figure 3E shows, dasatinib and PKC activation cause an increase of apoptotic cells (25% and 34%, respectively) without modifying necrotic population. Surprisingly, dasatinib+PMA combination induces an acute decrease on live cells, matched by a significant increase of apoptotic and necrotic cells.

PKC activation effect over STI571 and dasatinib effectiveness in PKCδ-silenced HMC- 1 cells. The results described confirm that PKC activation potentiates TyrK inhibitors effect on cell viability either in HMC-1^{560} or HMC-1^{560,816} cell line. It was reported that PKC is related with apoptosis in several cell lines. Specifically, Ca^{2+}-independent isoform PKCδ is associated with apoptotic pathway. Therefore, live, apoptotic and necrotic populations determination was next carried-out in PKCδ-silenced HMC-1 cells. The effectiveness of lipid-based transfection method is determined in both MC lines (Figure 4). In HMC-1^{560} cells, cytosolic PKCδ levels significantly diminish after 24 h (25% of decrease), 36 h (37%) and 48 h (50%) (Figures 4A and 4C). A similar result is obtained in HMC-1^{560,816} cells, since cytosolic PKCδ expression decreases 29%, 55% and 62% after 24, 36 and 48 h respectively (Figures 4B and 4D). PKC activation effect over STI571 and dasatinib mechanisms of action was next evaluated (Figure 5). As Figure 5A shows, PKCδ silencing partially blocks STI571 cytotoxic effect since cell viability rises from 52 to 70%, even though STI571-induced viability decrease is still significant in HMC-1^{560} cells. This effect only



Figure 4. *Determination of PKCδ silencing efficiency by western blott analysis in HMC-1 mast cell lines. PKCδ siRNA was incubated for 24, 36 and 48 h in HMC-1^{560} and HMC-1^{560,816} cell lines. (A) and (B) show a representative image of each condition in HMC-1^{560} and HMC-1^{560,816} cell line, respectively. (C) and (D) is the mean±SEM of three experiments in HMC-1^{560} and HMC-1^{560,816} cell line, respectively. Cytosolic PKCδ values were calculated respect to actin band intensity. *significant differences between non-silenced and PKCδ-silenced cells.*

happens after STI571 treatment, since cell viability is not modified under the remaining treatments. In HMC-1^{560,816} cells, PKCδ-silencing avoids dasatinib, PMA and dasatinib+PMA-induced cytotoxicities (Figure 5B). Once observed that STI571, dasatinib and PMA cytotoxic effects are PKCδ-dependent. Next, the determination of live, apoptotic and necrotic populations in HMC-1-PKCδ silenced cells is carried-out in order to clarify this PKCδ reliance. In HMC-1^{560} cells, PKCδ silencing completely blocks cytotoxic effects of all treatments tested (Figures 6C, 6D, 6E and 6F) except for STI571 treatment (Figure 6B), since apoptotic population suffers a slight increase despite PKCδ silencing (Figure 6G). For HMC-1^{560,816} cells, no modification is observed after dasatinib (Figure 7B), PMA (Figure 7C) and dasatinib+PMA (Figure 7D) treatments. Hence, the increase of necrotic cells previously observed in dasatinb+PMA-treated cells (Figure 3E) is abolished with PKCδ silencing.

Therefore, in addition to the apoptotic effect observed after STI571 and dasatinib in HMC-1^{560} and HMC-1^{560,816} cells, respectively, it can be concluded that PKCδ activation stimulates necrosis when TyrKs are inhibited, increasing TyrK inhibitors cytotoxicities.

Discussion

One of the most important groups utilised in SM treatment is the TyrK inhibitors. Their effectiveness against HMC-1 cell line and bone marrow cells has been widely described (9). Either STI571 or dasatinib are characterized by their cytotoxic effect against cells that have the bcr-abl oncoprotein in a constitutively activated state, but other TyrK receptors, such as c-kit, are also an important target for both compounds. The presence of Asp-816 to Val mutation avoids STI571 cytotoxic effect by interfering with drug binding in HMC-1^{560,816} cells, however, this blockage does not take place with Val-560 to Gly activating mutation (24). On the other hand, Asp-816 >Val mutation does not affect dasatinib mechanism of action and consequently cell death is observed after dasatinib treatment. Results shown herein indicate that TyrK inhibitor STI571 induces apoptotic cell death in HMC-1^{560} cells. These results are in accordance with those obtained in other cell lines (human colon adenocarcinoma cells and CML cell lines bcr/abl positive), in which STI571 increases caspase-3 activity, an indicator of apoptosis activation. Moreover, results presented indicate that, as for STI571, dasatinib also induces apoptosis



Figure 5. *Effect of tyrosine kinase inhibitors, STI571 and dasatinib, and PKC activation on cell viability in PKCδ-silenced HMC-1^{560} and HMC-1^{560,816} cell lines. Cells were incubated for 48 h with STI571, dasatinib and PMA at 37˚C. (A) and (B) results obtained in HMC-1^{560} and HMC-1^{560,816} cell lines, respectively. Mean±SEM of three experiments. *Significant differences between no silenced and PKCδ-silenced cells for the different treatments. #Significant differences between untreated and STI571 PKCδ-silenced cells.*

in HMC-1^{560} and HMC-1^{560,816} cell lines, in agreement with the results previously obtained for HMC-1^{560,816} cells (25). STI571 and dasatinib apoptotic activities are PKCδ-dependent, since PKCδ cytosolic levels decrease leads to TyrK inhibitors effect disappearance. It is important to note that dasatinib presents a higher PKCδ dependence than STI571. In this sense, in spite of having silenced the PKCδ isoform, an increase of apoptotic population is observed after STI571 treatment in HMC-1^{560} cells, unlike to that observed after dasatinib treatment. This fact might be related with dasatinib targets (Btk and Lyn proteins), since Lyn is a protein related to PKCδ isoform and both take part in degranulation pathway regulated by Src homology 2 domain-containing inositol-5'-phophatase (SHIP). In this regard, PKCδ and Lyn relationship has been widely described in antigen-induced MC degranulation (26). Therefore, considering the strong dependence of dasatinib mechanism of action by PKCδ, this isoform may be also considered an important target for this compound.

Results obtained demonstrate that apoptotic cell death induced by PKC activation is completely PKCδ-dependent in HMC-1^{560} and HMC-1^{560,816} cells. Phorbol esters role over cell death is controversial, since their effect is usually described as cytoprotective after a short incubation (27), since inhibit apoptosis in thymocytes, T lymphocytes and chronic lymphocytic leukemia B-cells (28), Jurkat leukemic T-cells (29) and nerve cells. In this case, phorbol esters neuroprotection occurs through an extensive phosphorylation pathway in which are involved extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK) and finally PKCδ (30). On the other hand, phorbol esters can also have an opposite role in several cell lines, such as human bronchial epithelial cells. Specifically, PKCδ is related with cell death caused by the carcinogen asbestos in these cells. Also, asbestos-induced cell death is described as PKCδ–dependent and nuclear PKCδ translocation takes place after its activation (23). Hence, this means that PKC activation can protect cells against cytotoxic agents or conversely to induce or potentiate cell death. In our case, PKC activation has an evident apoptotic effect over both HMC-1 cell lines. It is important to note that PKCδ activity is not exclusively related with apoptotic cell death, as it was widely described in the present study, but also with necrotic pathway (31). In fact, this PKCδ dual role has been previously described as dependent on the localization of the protein and the presence of pro- or antiapoptotic mediators (32).

PKC is a protein intimately related with MC activation, adhesion and migration (14, 33). MCs activation starts after antigen aggregation to FCεRI and is enhanced by SCF-c-kit binding. Also, Btk is the responsible of up regulating MC activation through FCεRI pathway. Specifically, Btk and Lyn have been described as the most important targets for dasatinib in neoplastic MCs and TyrK inhibitors were defined as potent modulators of MC degranulation (34, 35). Dasatinib inhibits human basophils IgE-dependent histamine release (35), while STI571 induces a decrease on histamine release in both HMC-1^{560} and HMC-1^{560,816} cell lines (36, 37). Therefore, either TyrK inhibition or PKC activation may regulate MC activation. Surprisingly, the effect obtained after TyrK and PKC pathways modulation is completely different, depending on the compound (STI571 or dasatinib). PKC activation induces a enhancer STI571 cytotoxic effect that implies a higher necrotic effect on HMC-1^{560} cells. However, long-term PMA incubation does not provoke any modification after dasatinib treatment, thus, both compounds might be sharing a similar pathway,



Figure 6. *Effect of 25 nM STI571, 0.012 μM dasatinib and 100 ng/ml PMA treatment in PKCδ–silenced HMC-1^{560} cells viability. HMC-1^{560} cells were incubated for 48 h at 37˚C with the different compounds. Live (botton left panel), apoptotic (botton right panel) and late apoptotic/necrotic cells (upper panel) were detected by Annexin V-FITC/PI staining. (A), (B), (C), (D), (E) and (F) represent one representative experiment of untreated, STI571, dasatinib, PMA, STI571+PMA and dasatinib+PMA treatments, respectively. (G) mean±SEM of the three experiments. **Significant differences between untreated and STI571-treated cells on apoptotic population.*

probably through PKCδ. In HMC-1^{560,816} cells, PKC activation and dasatinib cytotoxicities are additive, and as for STI571 in HMC-1^{560} cells, this fact is accompanied by a necrotic population increase. Interestingly, previous results obtained in our laboratory demonstrate that STI571 (in HMC-1^{560}) and dasatinib (in HMC-1^{560,816}) treatments lead to nuclear PKCδ translocation. Therefore, this PKCδ translocation might be related with a final extreme damage ending in necrotic cell death (present at 25% of the cells). In addition to PKC activation, the inhibition of this protein has



Figure 7. *Effect of 0.012 μM dasatinib and 100 ng/ml PMA treatments in PKCδ–silenced HMC-1^{560,816} cells viability. HMC-1^{560,816} cells were incubated for 48 h at 37˚C with the different compounds. Live (botton left panel), apoptotic (botton right panel) and late apoptotic/necrotic cells (upper panel) were detected by Annexin V-FITC/PI staining. (A), (B), (C) and (D) represent one representative experiment of untreated, dasatinib, PMA and dasatinib+PMA treatments, respectively. (E) mean±SEM of the three experiments.*

been also described as a potential target to induce cell death in multiple myeloma cells. In this regard, it is necessary to clarify that PKC inhibitors were previously described as an anti-cancer drugs. Specifically, midostaurin, which inhibits Ca^{2+}-dependent PKCs as well as acts as a TyrK inhibitor, induces an effectively HMC-1 cell death (19). Interestingly, a synergistic effect of midostaurin and dasatinib has been found in HMC-1 cell line (11), therefore a crosstalk between PKC regulation and TyrK inhibition might be taking place. In summary, results obtained in this study demonstrate that long-time PKC activation can be used as a potential tool in SM treatment, alone or in combination with TyrK inhibition.

Acknowledgements

This research has received funding from the following FEDER cofunded-grants: From CDTI and Technological Funds, supported by Ministerio de Economía y Competitividad, AGL2012-40185-CO2-01 and Consellería de Cultura, Educación e Ordenación Universitaria, GRC2013-016, and through Axencia Galega de Innovación, Spain, ITC-20133020 SINTOX, IN852A 2013/16-3 MYTIGAL. From CDTI under ISIP Programme, Spain, IDI-20130304 APTAFOOD. From the European Union's Seventh Framework Programme managed by REA – Research Executive Agency (FP7/2007-2013) under grant agreement Nos. 265409 μAQUA, 315285 CIGUATOOLS and 312184 PHARMASEA. Araceli Tobío Ageitos is supported by a fellowship from Programa de Formación de Profesorado Universitario (AP2008/03904), Ministerio de Educación, Spain.

References

1 Metz M, Siebenhaar F and Maurer M: Mast cell functions in the innate skin immune system. Immunobiology *213*: 251-260, 2008.
2 Valent P, Horny HP, Triggiani M and Arock M: Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol *156*: 119-127, 2011.
3 Valent P: Mast cell activation syndromes: definition and classification. Allergy *68*: 417-424, 2013.
4 Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, Castells M, Escribano L, Hartmann K, Lieberman P *et al*: Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol *157*: 215-225, 2012.
5 Nilsson G and Metcalfe DD: Contemporary issues in mast cell biology. Allergy Asthma Proc *17*: 59-63, 1996.
6 Bodemer C, Hermine O, Palmerini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A *et al*: Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol *130*: 804-815, 2010.
7 Agis H, Sotlar K, Valent P and Horny HP: Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. Leuk Res *29*: 1227-1232, 2005.
8 Brazzelli V, Grasso V and Borroni G: Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013.
9 Ustun C, DeRemer DL, Akin C: Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res *35*: 1143-1152, 2011.

10 Kosior K, Lewandowska-Grygiel M and Giannopoulos K: Tyrosine kinase inhibitors in hematological malignancies. Postepy Hig Med Dosw (Online) *65*: 819-828, 2011.
11 Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D *et al*: Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica *92*: 1451-1459, 2007.
12 Ozawa K, Yamada K, Kazanietz MG, Blumberg PM and Beaven MA: Different isozymes of protein kinase C mediate feedback inhibition of phospholipase C and stimulatory signals for exocytosis in rat RBL-2H3 cells. J Biol Chem 268: 2280-2283, 1993.
13 Ozawa K, Szallasi Z, Kazanietz MG, Blumberg PM, Mischak H, Mushinski JF and Beaven MA: Ca(2+)-dependent and Ca(2+)-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with Ca^{2+} and purified isozymes in washed permeabilized cells. J Biol Chem *268*: 1749-1756, 1993.
14 Peng Z and Beaven MA: An essential role for phospholipase D in the activation of protein kinase C and degranulation in mast cells. J Immunol *174*: 5201-5208, 2005.
15 Blank U and Rivera J: The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol *25*: 266-273, 2004.
16 Kawakami Y, Kitaura J, Satterthwaite AB, Kato RM, Asai K, Hartman SE, Maeda-Yamamoto M, Lowell CA, Rawlings DJ, Witte ON *et al*: Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol *165*: 1210-1219, 2000.
17 Nechushtan H, Leitges M, Cohen C, Kay G and Razin E: Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase Cbeta. Blood *95*: 1752-1757, 2000.
18 Kalesnikoff J, Lam V and Krystal G: SHIP represses mast cell activation and reveals that IgE alone triggers signaling pathways which enhance normal mast cell survival. Mol Immunol *38*: 1201-1206, 2002.
19 Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D *et al*: PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood *107*: 752-759, 2006.
20 Shah NP, Lee FY, Luo R, Jiang Y, Donker M and Akin C: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood *108*: 286-291, 2006.
21 Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G and Longley BJ: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood *99*: 1741-1744, 2002.
22 Kumbrink J and Kirsch KH: p130Cas acts as survival factor during PMA-induced apoptosis in HL-60 promyelocytic leukemia cells. Int J Biochem Cell Biol *45*: 531-535, 2013.
23 Kim H, Zamel R, Bai XH and Liu M: PKC Activation Induces Inflammatory Response and Cell Death in Human Bronchial Epithelial Cells. PLoS One *8*: e64182, 2013.
24 Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ and Metcalfe DD: Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol *31*: 686-692, 2003.
25 Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hormann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J *et al*: KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood *118*: 1885-1898, 2011.
26 Leitges M, Gimborn K, Elis W, Kalesnikoff J, Hughes MR, Krystal G and Huber M: Protein kinase C-delta is a negative regulator of antigen-induced mast cell degranulation. Mol Cell Biol *22*: 3970-3980, 2002.
27 Lin KC, Liu PS, Peng PY and Chueh SH: Acute phorbol ester treatment inhibits thapsigargin-induced cell death in porcine aortic smooth muscle cells. Eur J Pharmacol 686: 8-15, 2012.
28 McConkey DJ, Hartzell P, Jondal M and Orrenius S: Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J Biol Chem *264*: 13399-13402, 1989.
29 Ruiz-Ruiz MC, Izquierdo M, de Murcia G and Lopez-Rivas A: Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis. Eur J Immunol *27*: 1442-1450, 1997.
30 Maher P: How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J Neurosci *21*: 2929-2938, 2001.
31 Jin H, Kanthasamy A, Ghosh A, Yang Y, Anantharam V and Kanthasamy AG: alpha-Synuclein negatively regulates protein kinase Cdelta expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci *31*: 2035-2051, 2011.
32 Basu A and Pal D: Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in cell survival and cell death. ScientificWorldJournal *10*: 2272-2284, 2010.
33 Tobio A, Alfonso A and Botana LM: C-kit mutations and PKC crosstalks: PKC translocates to nucleous only in cells HMC(5)(6)(0),(8)(1)(6). J Cell Biochem *112*: 2637-2651, 2011.
34 Herrmann H, Blatt K, Ghanim V, Kneidinger M, Marth K, Valenta R and Valent P: Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release. Int Arch Allergy Immunol *159*: 15-22, 2012.
35 Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H *et al*: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood *111*: 3097-3107, 2008.
36 Lober K, Alfonso A, Escribano L and Botana LM: Influence of the tyrosine kinase inhibitors STI571 (Glivec), lavendustin A and genistein on human mast cell line (HMC-1(560)) activation. J Cell Biochem *103*: 1076-1088, 2008.
37 Lober K, Alfonso A, Escribano L and Botana LM: STI571 (Glivec) affects histamine release and intracellular pH after alkalinisation in HMC-1560, 816. J Cell Biochem *103*: 865-876, 2008.

Received March 11, 2014
Revised May 6, 2014
Accepted May 7, 2014

Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction;* (d) *Materials and Methods/Patients and Methods;* (e) *Results;* (f) *Discussion;* (g) *Acknowledgements;* (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of “Index Medicus” and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.
For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.